Abstract
Cells produce proteases as inactive zymogens. Here, we demonstrate that this tactic can extend beyond proteases. By linking the N and C termini of ribonuclease A, we obstruct the active site with the amino acid sequence recognized by plasmepsin II, a highly specific protease from Plasmodium falciparum. We generate new N and C termini by circular permutation. In the presence of plasmepsin II, a ribonuclease zymogen gains ∼103-fold in catalytic activity and maintains high conformational stability. We conclude that zymogen creation provides a new and versatile strategy for the control of enzymatic activity, as well as the potential development of chemotherapeutic agents.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Accession codes
References
Von Der Helm, K., Korant, B.D. & Cheronis, J.C. Proteases as Targets for Therapy. (Springer-Verlag, Heidelberg; 2000).
Smith, J. & Simons, C. Proteinase and Peptidase Inhibition: Recent Potential Targets for Drug Development. (Taylor & Francis, London; 2002).
Kühne, W. Ueber die verdauung der eiweissstoffe durch den pankreassaft. Virchows Arch. 39, 130–174 (1867).
Khan, A.R. & James, M.N.G. Molecular mechanisms for the conversion of zymogens to active proteolytic enzymes. Protein Sci. 7, 815–836 (1998).
Laskowski, M. Jr., Qasim, M.A. & Lu, S.M. Interaction of standard mechanism, canonical protein inhibitors with serine proteases. in Protein–Protein Recognition (ed. Kleanthous, C.) 228–279 (Oxford University Press, Oxford; 2000).
Lazure, C. The peptidase zymogen proregions: Nature's way of preventing undesired activation and proteolysis. Curr. Pharm. Des. 8, 509–529 (2002).
Leland, P.A. & Raines, R.T. Cancer chemotherapy — ribonucleases to the rescue. Chem. Biol. 8, 405–413 (2001).
Kleanthous, C. & Pommer, A.J. Nuclease inhibitors. in Protein–Protein Recognition (ed. Kleanthous, C.) 280–311 (Oxford University Press, Oxford; 2000).
D'Alessio, G. & Riordan, J.F. Ribonucleases: Structures and Functions. (Academic Press, New York; 1997).
Raines, R.T. Ribonuclease A. Chem. Rev. 98, 1045–1065 (1998).
Goldenberg, D.P. & Creighton, T.E. Circular and circularly permuted forms of bovine pancreatic trypsin inhibitor. J. Mol. Biol. 165, 407–413 (1983).
Todd, A.E., Orengo, C.A. & Thornton, J.M. Plasticity of enzyme active sites. Trends Biochem. Sci. 27, 419–426 (2002).
Grishin, N.V. Fold change in evolution of protein structures. J. Struct. Biol. 134, 167–185 (2001).
Silva, A.M. et al. Structure and inhibition of plasmepsin II, a hemoglobin-degrading enzyme from Plasmodium falciparum. Proc. Natl. Acad. Sci. USA 93, 10034–10039 (1996).
Klemba, M. & Goldberg, D.E. Biological roles of proteases in parasitic protozoa. Annu. Rev. Biochem. 7, 275–305 (2002).
Goldberg, D.E. et al. Hemoglobin degradation in the human malaria pathogen Plasmodium falciparum: a catabolic pathway initiated by a specific aspartic protease. J. Exp. Med. 173, 961–969 (1991).
Francis, S.E., Sullivan, D.J. Jr. & Goldberg, D.E. Hemoglobin metabolism in the malaria parasite Plasmodium falciparum. Annu. Rev. Microbiol. 51, 97–123 (1997).
Francis, S.E., Banerjee, R. & Goldberg, D.E. Biosynthesis and maturation of the malaria aspartic hemoglobinases plasmepsins I and II. J. Biol. Chem. 272, 14961–14968 (1997).
Bernstein, N.K., Cherney, M.M., Loetscher, H., Ridley, R.G. & James, M.N. Crystal structure of the novel aspartic proteinase zymogen proplasmepsin II from Plasmodium falciparum. Nat. Struct. Biol. 6, 32–37 (1999).
Klink, T.A. & Raines, R.T. Conformational stability is a determinant of ribonuclease A cytotoxicity. J. Biol. Chem. 275, 17463–17467 (2000).
delCardayré, S.B. et al. Engineering ribonuclease A: production, purification, and characterization of wild-type enzyme and mutants at Gln11. Protein Eng. 8, 261–273 (1995).
Leland, P.A., Schultz, L.W., Kim, B.M. & Raines, R.T. Ribonuclease A variants with potent cytotoxic activity. Proc. Natl. Acad. Sci. USA 95, 10407–10412 (1998).
Parsell, D.A. & Sauer, R.T. The structural stability of a protein is an important determinant of its proteolytic susceptibility in Escherichia coli. J. Biol. Chem. 264, 7590–7595 (1989).
Bretscher, L.E., Abel, R.L. & Raines, R.T. A ribonuclease A variant with low catalytic activity but high cytotoxicity. J. Biol. Chem. 275, 9893–9896 (2000).
Fawell, S. et al. Tat-mediated delivery of heterologous proteins into cells. Proc. Natl. Acad. Sci. USA 91, 664–668 (1994).
Haigis, M.C., Kurten, E.L., Abel, R.L. & Raines, R.T. KFERQ sequence in ribonuclease A-mediated cytotoxicity. J. Biol. Chem. 277, 11576–11581 (2002).
Leland, P.A., Staniszewski, K.E., Kim, B.M. & Raines, R.T. Endowing human pancreatic ribonuclease with toxicity for cancer cells. J. Biol. Chem. 276, 43095–43102 (2001).
Mikulski, S.M. et al. Phase II trial of a single weekly intravenous does of ranpirnase in patients with unresectable malignant mesothelioma. J. Clin. Oncol. 20, 274–281 (2002).
Wlodawer, A., Svensson, L.A., Sjölin, L. & Gilliland, G.L. Structure of phosphate-free ribonuclease A refined at 1.26 Å. Biochemistry 27, 2705–2717 (1988).
Westling, J. et al. Plasmodium falciparum, P. vivax and P. malariae: a comparison of the active site properties of plasmepsins cloned and expressed from three different species of the malaria parasite. Exp. Parasitol. 87, 185–193 (1997).
Hill, J. et al. High level expression and characterisation of Plasmepsin II, an aspartic proteinase from Plasmodium falciparum. FEBS Lett. 352, 155–158 (1994).
Kelemen, B.R. et al. Hypersensitive substrate for ribonucleases. Nucleic Acids Res. 27, 3696–3701 (1999).
Klink, T.A., Woycechowsky, K.J., Taylor, K.M. & Raines, R.T. Contribution of disulfide bonds to the conformational stability and catalytic activity of ribonuclease A. Eur. J. Biochem. 267, 566–572 (2000).
Westling, J. et al. Active site specificity of plasmepsin II. Protein Sci. 8, 2001–2009 (1999).
Acknowledgements
We thank C. Park and D.H. Rich for contributive discussions, and B.M. Dunn for a plasmpesin II expression system. P.P. was supported by the Asian Partnership Initiative of Mahidol University and the University of Wisconsin, Madison. S.M.F. was supported by a Biotechnology Training Grant from the NIH. This work was supported by a grant to R.T.R. from the NIH.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Plainkum, P., Fuchs, S., Wiyakrutta, S. et al. Creation of a zymogen. Nat Struct Mol Biol 10, 115–119 (2003). https://doi.org/10.1038/nsb884
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/nsb884
This article is cited by
-
Ribonuclease zymogen induces cytotoxicity upon HIV-1 infection
AIDS Research and Therapy (2021)
-
Development of latent Interferon alpha 2b as a safe therapeutic for treatment of Hepatitis C virus infection
Scientific Reports (2019)
-
1H, 13C and 15N resonance assignments of the Onconase FL-G zymogen
Biomolecular NMR Assignments (2013)